Stockscreener 앱 받기
35.23
0.82%
0.50
전일 마감가:
$34.73
열려 있는:
$34.8
하루 거래량:
23,356
Relative Volume:
0.04
시가총액:
$1.80B
수익:
$276.26M
순이익/손실:
$16.52M
주가수익비율:
114.46
EPS:
0.3078
순현금흐름:
$24.75M
1주 성능:
+1.52%
1개월 성능:
-1.75%
6개월 성능:
-13.26%
1년 성능:
-14.43%
1일 변동 폭
$34.44
$35.23
1주일 범위
$34.15
$36.35
52주 변동 폭
$28.95
$45.97
베리셀 Stock (VCEL) Company Profile
명칭
Vericel Corp
전화
(734) 930-5555
주소
64 SIDNEY ST., CAMBRIDGE, MA
Compare VCEL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VCEL
Vericel Corp
|
35.23 | 1.77B | 276.26M | 16.52M | 24.75M | 0.3078 |
VRTX
Vertex Pharmaceuticals Inc
|
435.38 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
641.00 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.95 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.51 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.13 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
베리셀 Stock (VCEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-08-09 | 개시 | Canaccord Genuity | Buy |
| 2024-06-20 | 개시 | TD Cowen | Buy |
| 2024-01-25 | 업그레이드 | Truist | Hold → Buy |
| 2023-08-08 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-11-09 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-14 | 재개 | Stephens | Overweight |
| 2021-01-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-12-18 | 개시 | Stephens | Overweight |
| 2020-09-17 | 개시 | Truist | Buy |
| 2019-10-09 | 개시 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Needham | Buy → Hold |
| 2018-08-08 | 재확인 | Needham | Buy |
| 2018-07-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2018-04-04 | 개시 | Leerink Partners | Outperform |
| 2018-03-06 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-03-06 | 재확인 | Needham | Buy |
| 2018-03-05 | 재확인 | BTIG Research | Buy |
| 2017-06-21 | 개시 | BTIG Research | Buy |
| 2017-03-13 | 재확인 | Needham | Buy |
| 2016-12-22 | 개시 | Piper Jaffray | Overweight |
| 2016-11-09 | 재확인 | Needham | Buy |
| 2016-04-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-03-11 | 업그레이드 | Needham | Hold → Buy |
모두보기
베리셀 주식(VCEL)의 최신 뉴스
Q1 2026 Vericel Corp Earnings Call Transcript - GuruFocus
Q3 2025 Vericel Corp Earnings Call Transcript - GuruFocus
Vericel (VCEL) amends bylaws to reflect new Burlington, MA global headquarters - Stock Titan
Vericel Corporation $VCEL Stock Position Reduced by Truist Financial Corp - MarketBeat
Vericel (VCEL) director McLaughlin exercises options and sells 7,000 shares - Stock Titan
VCEL Stock Price, Quote & Chart | VERICEL CORP (NASDAQ:VCEL) - ChartMill
Vericel CorporationCommon Stock (NQ: VCEL - FinancialContent
Vericel director Paul Wotton sells $327,425 in company stock By Investing.com - Investing.com Australia
Insider Sell: Paul Wotton Sells 10,000 Shares of Vericel Corp (V - GuruFocus
Vericel director Paul Wotton sells $327,425 in company stock - Investing.com
Director Paul K. Wotton sells 10,000 Vericel (VCEL) shares around $33 - Stock Titan
Issuer (NASDAQ: VCEL) notifies sale of 7,000 common shares - Stock Titan
Vericel (VCEL) Eps Diluted (TTM) - Zacks Investment Research
TradingKey - TradingKey
[144] Vericel Corp SEC Filing - Stock Titan
What is HC Wainwright's Estimate for Vericel Q4 Earnings? - MarketBeat
Analysts Have Made A Financial Statement On Vericel Corporation's (NASDAQ:VCEL) First-Quarter Report - Yahoo Finance
Vericel Corporation (NASDAQ:VCEL) Q1 2026 Earnings Call Transcript - Insider Monkey
Vericel Corp (NASDAQ:VCEL): A Prime Example of Affordable Growth - ChartMill
Vericel Q1 Earnings Call Highlights - Yahoo Finance
Insider Sell: Mara Joseph Anthony Jr Sells 5,000 Shares of Veric - GuruFocus
Analysts Offer Insights on Healthcare Companies: Vericel (VCEL) and BridgeBio Pharma (BBIO) - The Globe and Mail
Vericel (VCEL) CFO 10b5-1 sale leaves 21,009 shares held - Stock Titan
Vericel (NASDAQ: VCEL) accounting chief sells 4,855 shares - Stock Titan
VCEL Maintains Buy Rating by HC Wainwright & Co. -- Price Target Raised to $64.00 - GuruFocus
Vericel Q1 2026 slides: 30% revenue growth drives guidance raise By Investing.com - Investing.com Australia
MSN Money - MSN
VCEL PE Ratio & Valuation, Is VCEL Overvalued - Intellectia AI
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance - Ortho Spine News
Vericel Q1 2026 slides: 30% revenue growth drives guidance raise - Investing.com
Earnings call transcript: Vericel’s Q1 2026 beats forecasts, stock surges - Investing.com
Jonathan Siegal files Form 144 — VCEL (NASDAQ: VCEL) sells 3,433 shares - Stock Titan
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Vericel Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Vericel Corp 1Q 2026: Revenue $68.43M, EPS ($0.12) — 10-Q Summary - TradingView
BARDA burns contract backs NexoBrid growth at Vericel (VCEL) - Stock Titan
Vericel Corp (NASDAQ:VCEL) Smashes Q1 Estimates, Raises Full-Year Outlook as MACI and Burn Care Surge - ChartMill
VERICEL ($VCEL) Releases Q1 2026 Earnings - Quiver Quantitative
Vericel Reports Q1 2026: Revenue Up 30% to $68.4M, Adjusted EBITDA $9.6M - TradingView
Vericel (NASDAQ: VCEL) lifts 2026 outlook after 30% Q1 revenue gain - Stock Titan
Vericel Corporation Reports 30% Revenue Growth to $68.4 Million in Q1 2026, Raises Full-Year Guidance to $326-$336 Million - Quiver Quantitative
Burn care sales surge 91% as Vericel lifts 2026 revenue target - Stock Titan
VCEL (NASDAQ: VCEL) Form 144 lists 3,433 shares valued $130,454; vesting noted - Stock Titan
Vericel faces earnings test as Q1 loss looms after FDA approval - Investing.com Australia
Vericel faces earnings test as Q1 loss looms after FDA approval By Investing.com - Investing.com South Africa
Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight - GlobeNewswire Inc.
Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Technical Setup Opportunity - ChartMill
베리셀 (VCEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.25%
0.46%
자본화:
|
볼륨(24시간):